Skip to main content

Research Repository

Advanced Search

All Outputs (8)

Predictors of short term mortality in heart failure - insights from the Euro Heart Failure survey (2008)
Journal Article
Velavan, P., Khan, N. K., Goode, K., Rigby, A. S., Loh, P. H., Komajda, M., …Cleland, J. G. (2010). Predictors of short term mortality in heart failure - insights from the Euro Heart Failure survey. International journal of cardiology, 138(1), 63-69. https://doi.org/10.1016/j.ijcard.2008.08.004

Objective: To identify factors associated with short term mortality in hospitalised patients with heart failure. Background: Hospitalisation is frequent in patients with heart failure and is associated with a high mortality. Methods: The Euro Heart F... Read More about Predictors of short term mortality in heart failure - insights from the Euro Heart Failure survey.

Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease (2008)
Journal Article
Wakil, A., Rigby, A. S., Clark, A. L., Kallvikbacka-Bennett, A., & Atkin, S. L. (2008). Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. European journal of endocrinology, 159(4), R11-R14. https://doi.org/10.1530/eje-08-0365

OBJECTIVE: Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease. However, the dose of cabergoline used to treat hyp... Read More about Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease.

A1C variability and the risk of microvascular complications in type 1 diabetes: Data from the diabetes control and complications trial (2008)
Journal Article
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2008). A1C variability and the risk of microvascular complications in type 1 diabetes: Data from the diabetes control and complications trial. Diabetes Care, 31(11), 2198-2202. https://doi.org/10.2337/dc08-0864

OBJECTIVE—Debate remains as to whether short- or long-term glycemic instability confers a risk of microvascular complications in addition to that predicted by mean glycemia alone. In this study, we analyzed data from the Diabetes Control and Complica... Read More about A1C variability and the risk of microvascular complications in type 1 diabetes: Data from the diabetes control and complications trial.

The accurate staging of ovarian cancer using 3T magnetic resonance imaging - a realistic option (2008)
Journal Article
Booth, S., Turnbull, L., Poole, D., & Richmond, I. (2008). The accurate staging of ovarian cancer using 3T magnetic resonance imaging - a realistic option. BJOG: An International Journal of Obstetrics and Gynaecology, 115(7), 894-901. https://doi.org/10.1111/j.1471-0528.2008.01716.x

Objectives: The aim of the study was to determine whether staging primary ovarian cancer using 3.0 Tesla (3T) magnetic resonance imaging (MRI) is comparable to surgical staging of the disease. Design: A retrospective study consisting of a search of t... Read More about The accurate staging of ovarian cancer using 3T magnetic resonance imaging - a realistic option.

An amygdala response to fearful faces with covered eyes (2008)
Journal Article
Asghar, A. U., Chiu, Y. C., Hallam, G., Liu, S., Mole, H., Wright, H., & Young, A. W. (2008). An amygdala response to fearful faces with covered eyes. Neuropsychologia, 46(9), 2364-2370. https://doi.org/10.1016/j.neuropsychologia.2008.03.015

Findings of amygdala responsiveness to the eye region of fearful faces raise the question of whether eye widening is the only facial cue involved. We used fMRI to investigate the differential amygdala response to fearful versus neutral stimuli for fa... Read More about An amygdala response to fearful faces with covered eyes.

The timing of development and subsequent clinical course of heart failure after a myocardial infarction (2008)
Journal Article
Torabi, A., Cleland, J. G., Khan, N. K., Loh, P. H., Clark, A. L., Alamgir, F., …Goode, K. (2008). The timing of development and subsequent clinical course of heart failure after a myocardial infarction. European Heart Journal, 29(7), 859-870. https://doi.org/10.1093/eurheartj/ehn096

Aims: Myocardial infarction (MI) is a common cause of heart failure (HF), which may develop early and persist or resolve, or develop late. The cumulative incidence, persistence, and resolution of HF after MI are poorly described. The aim of this stud... Read More about The timing of development and subsequent clinical course of heart failure after a myocardial infarction.

Brain imaging of acupuncture: comparing superficial with deep needling (2008)
Journal Article
MacPherson, H., Green, G., Nevado, A., Lythgoe, M. F., Lewith, G., Devlin, R., …Asghar, A. U. R. (2008). Brain imaging of acupuncture: comparing superficial with deep needling. Neuroscience letters, 434(1), 144-149. https://doi.org/10.1016/j.neulet.2008.01.058

The difference between superficial and deep needling at acupuncture points has yet to be mapped with functional magnetic resonance imaging (fMRI). Using a 3 T MRI, echo planar imaging data were acquired for 17 right-handed healthy volunteer participa... Read More about Brain imaging of acupuncture: comparing superficial with deep needling.

Fluvastatin reduces oxidative damage in human vascular endothelial cells by upregulating Bcl-2 (2008)
Journal Article
Xu, S. Z., Zhong, W., Watson, N. M., Dickerson, E., Wake, J. D., Lindow, S. W., …Atkin, S. L. (2008). Fluvastatin reduces oxidative damage in human vascular endothelial cells by upregulating Bcl-2. Journal of thrombosis and haemostasis : JTH, 6(4), 692-700. https://doi.org/10.1111/j.1538-7836.2008.02913.x

Background: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been widely used in clinical practise and their efficacy in reducing cardiovascular risk has been well described. Objectives: To investigate the effect of low doses... Read More about Fluvastatin reduces oxidative damage in human vascular endothelial cells by upregulating Bcl-2.